These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 7283558

  • 21. Diagnostic value of urine deoxypyridinoline for detecting bone metastases in breast cancer patients.
    Hou MF, Lin SB, Yuan SS, Tsai LY, Tsai SM, Hsieh JS, Huang TJ.
    Ann Clin Lab Sci; 2003; 33(1):55-61. PubMed ID: 12661898
    [Abstract] [Full Text] [Related]

  • 22. Relevance of hydroxyproline excretion to bone metastasis in breast cancer.
    Gielen F, Dequeker J, Drochmans A, Wildiers J, Merlevede M.
    Br J Cancer; 1976 Sep; 34(3):279-85. PubMed ID: 974001
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Procollagen type I carboxy-terminal propeptide as a marker of osteoblastic bone metastases.
    Francini G, Gonnelli S, Petrioli R, Bruni S, Marsili S, Aquino A, Camporeale A.
    Cancer Epidemiol Biomarkers Prev; 1993 Sep; 2(2):125-9. PubMed ID: 8467247
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. [Hydroxyproline excretion as an index for the evaluation of metabolic bone changes].
    Mühlbach R.
    Beitr Orthop Traumatol; 1966 Oct; 13(10):606-8. PubMed ID: 5977397
    [No Abstract] [Full Text] [Related]

  • 28. Urinary hydroxyproline excretion in carcinoma of the breast.
    Cuschieri A, Felgate RA.
    Br J Exp Pathol; 1972 Jun; 53(3):237-41. PubMed ID: 5055709
    [Abstract] [Full Text] [Related]

  • 29. Hydroxyproline excretion in patients with breast cancer and response to treatment.
    Powles TJ, Leese CL, Bondy PK.
    Br Med J; 1975 Apr 26; 2(5964):164-6. PubMed ID: 1125725
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Prognostic significance of bone metastasis from breast cancer.
    Yamashita K, Koyama H, Inaji H.
    Clin Orthop Relat Res; 1995 Mar 26; (312):89-94. PubMed ID: 7634621
    [Abstract] [Full Text] [Related]

  • 32. [The biochemical markers of bone remodeling in cancer patients with skeletal involvement].
    Liubimova NV, Bronnikov IIu, Robins SP, Trapeznikova MF, Kushlinskiĭ NE.
    Vopr Onkol; 2000 Mar 26; 46(3):290-7. PubMed ID: 10976274
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Comparison of 24-hour urinary protein and protein-to-creatinine ratio in the assessment of proteinuria.
    Wahbeh AM, Ewais MH, Elsharif ME.
    Saudi J Kidney Dis Transpl; 2009 May 26; 20(3):443-7. PubMed ID: 19414948
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Hydroxyproline excretion in malignant neoplastic disease.
    Hosley HF, Taft EG, Olson KB, Gates S, Beebe RT.
    Arch Intern Med; 1966 Dec 26; 118(6):565-71. PubMed ID: 5925444
    [No Abstract] [Full Text] [Related]

  • 38. [Effects of hormone replacement therapy in bone resorption, in post-menopausal women].
    Villaseca P, Arteaga E, Campusano C, López JM, Rojas A, Nazar G, O'Brien A.
    Rev Med Chil; 1996 Dec 26; 124(12):1439-46. PubMed ID: 9334477
    [Abstract] [Full Text] [Related]

  • 39. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
    Pollmann D, Siepmann S, Geppert R, Wernecke KD, Possinger K, Lüftner D.
    Anticancer Res; 2007 Dec 26; 27(4A):1853-62. PubMed ID: 17649784
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.